A recent article published in the Journal of Public Library of Science, has provided findings of a new study that “nicotine chewing gum, lozenges and inhalers designed to help people to give up smoking may have the potential to cause cancer …”
Continue reading " Nicotine Gum & Lozenges: Increased Risk of Cancer? " »
At the end of February, the FDA ordered that a "black box" warning highlighting the risk of tardive dyskinesia ("TD") and other serious neurological side effects be placed on all drugs that contain metoclopramide, including Reglan. Although the FDA has long been aware of the risk of TD when dopamine blockers such as Reglan are used, apparently the drug is still being prescribed for longer periods of time than the 4-12 week recommendation, which only further increases the likelihood of developing TD, an untreatable disorder with life-altering, sometimes permanent, symptoms.
Continue reading " FDA finally orders Black Box on Reglan and others containing metoclopramide " »
As we reported in October, pharmaceutical drug manufacturer, Genentech, was required by the Food and Drug Administration (FDA) to put a black boxed warning on the labeling for Raptiva regarding its association with dangerous and life-threatening infections like progressive multifocal leukoencephalopathy ("PML"). Today, Genentech voluntarily withdrew Raptiva, a psoriasis drug, from the market as a result of those risks.
Continue reading " Psoriasis Drug - Raptiva - Withdrawn From the Market " »
